TCG Crossover Management as of Dec. 31, 2022
Portfolio Holdings for TCG Crossover Management
TCG Crossover Management holds 21 positions in its portfolio as reported in the December 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Iveric Bio Comm | 19.4 | $110M | 5.1M | 21.41 | |
| Madrigal Pharmaceuticals Comm (MDGL) | 14.8 | $84M | 288k | 290.25 | |
| Cogent Biosciences Comm (COGT) | 7.4 | $42M | 3.6M | 11.56 | |
| Cymabay Therapeutics Comm | 6.5 | $37M | 5.9M | 6.27 | |
| Geron Corp Comm (GERN) | 6.5 | $37M | 15M | 2.42 | |
| Silence Therapeutics Adrs (SLN) | 5.7 | $32M | 2.1M | 15.25 | |
| Aerovate Therapeutics Comm (AVTE) | 5.6 | $32M | 1.1M | 29.30 | |
| Viridian Therapeutics Comm (VRDN) | 5.1 | $29M | 984k | 29.21 | |
| Ventyx Biosciences Comm (VTYX) | 4.6 | $26M | 787k | 32.79 | |
| Kalvista Pharmaceuticals Comm (KALV) | 4.1 | $23M | 3.4M | 6.76 | |
| Vectivbio Holding Comm | 3.6 | $20M | 2.3M | 8.66 | |
| Aclaris Therapeutics Comm (ACRS) | 3.2 | $18M | 1.1M | 15.75 | |
| Kura Oncology Comm (KURA) | 3.1 | $18M | 1.4M | 12.41 | |
| Immunovant Comm (IMVT) | 2.7 | $15M | 855k | 17.75 | |
| Tyra Biosciences Comm (TYRA) | 2.7 | $15M | 2.0M | 7.60 | |
| Moonlake Immunotherapeutics Comm (MLTX) | 1.9 | $11M | 1.0M | 10.50 | |
| Entrada Therapeutics Comm (TRDA) | 1.4 | $7.9M | 585k | 13.52 | |
| Merus Bv Comm (MRUS) | 0.8 | $4.6M | 300k | 15.47 | |
| Cabaletta Bio Comm (CABA) | 0.8 | $4.5M | 487k | 9.25 | |
| Alpine Immune Sciences Comm (ALPN) | 0.3 | $1.9M | 253k | 7.35 | |
| Elevation Oncology Comm (ELEV) | 0.0 | $274k | 288k | 0.95 |
